Fig. 4.

Adoptive transfer with M3–9-M primed T cells plus dendritic cell vaccination eradicates 10 day M3–9-M tumors. A: T cells (2.25 × 10⁶ CD4 and 2.25 × 10⁶ CD8 cells) from mice vaccinated as in 2B (primed T cells, harvested on day 83 post-vaccine) versus control mice (naive T cells) were administered IV to Rag1^−/− mice or C56BL/6 (F.B6) mice 1 day following administration of 1 × 10⁴ viable M3–9-M cells. C57BL/6 mice receiving primed T cells show significantly diminished tumor growth and improved survival compared to mice receiving no T cells or naive T cells. C57BL/6 mice receiving no T cells survived significantly longer than Rag1^−/− mice receiving no T cells, and C57BL/6 mice receiving primed T cells also had significantly diminished tumor growth and improved survival compared to Rag1^−/− mice receiving primed T cells. B: Adoptive transfer of primed T cells (as in Fig. 2B) plus DC vaccine (as in Fig. 2C) on day 10 post-tumor challenge results in complete control of M3–9-M tumors. Tumor growth curves from mice treated on day 10 post-tumor challenge with either unpulsed DCs or M3–9-M-pulsed DCs and/or primed T cells or naïve T cells. Mice receiving M3–9-M-pulsed DC vaccination plus primed T cells showed complete control of tumors growth (P = 0.0006 compared to mice receiving unpulsed DCs vaccine or naive T cells). Mice receiving the M3–9-M-pulsed DCs only showed a significant delay in tumor growth (P = 0.026), and mice receiving only primed T cells showed a trend toward slower tumor growth, but it was not significant compared to controls. Mice receiving both M3–9-M-pulsed DCs plus primed T cells had 100% tumor-free survival compared to control mice (P = 0.007).